ライフサイエンスコーパス: adverse

1 The risk for any adverse birth outcome was lower among infants exposed from co

2 lifornia spanning 2005 to 2010 and estimated PTBs and other adverse birth outcomes for infants borne by non-Hispanic blac

3 ns and confounding factors, such as substance use, previous adverse birth outcomes, and demographic factors.

4 us and categorical associations between arginine intake and adverse birth outcomes.

5 In-hospital major adverse cardiac and cerebral events occurred in 2.0% in fTRA

6 Major adverse cardiac events occurred in 1.1% and 4.2% of everolimu

7 Secondary end points included clinical outcomes (major adverse cardiac events), use of healthcare resources, and imp

8 a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events.

9 e risk of coronary heart disease by 27% (P=0.033) and major adverse cardiovascular events by 25% (P=0.037) during the ini

10 33), 1.61 (0.87 to 2.97), and 3.09 (0.96 to 8.78) for major adverse cardiovascular events, hospitalizations, and vascular

11 g number of cardiovascular risk factors at target and major adverse cardiovascular outcomes among patients with T1DM.

12 s of years thanks to its ability to resist and adapt to the adverse conditions it encounters upon infection.

13 The most common adverse effect was decreased blood calcium (68.9% vs 59.8%).

14 hways through which clozapine may act to cause this serious adverse effect.

15 ntial mechanism for the effects of sildenafil that, through adverse effects on mitochondrial function and endoplasmic ret

16 ith most patients; however, some GBCAs have a small risk of adverse effects, including nephrogenic systemic fibrosis (NSF

17 control, and 16% to 29% of patients reported opioid-induced adverse effects.

18 rther research is needed to assess longer-term efficacy and adverse effects.

19 ecular switch that dictates cell fate following exposure to adverse environments.

20 The most common serious adverse event in the active surveillance group was myocardial

21 The Food and Drug Administration Adverse Event Reporting System (FAERS) remains the primary so

22 Mid-frequency to high-frequency hearing loss, an expected adverse event, was documented in all participants.

23 Adverse events (eg, lethargy, diarrhoea, rash, and nausea) im

24 ted with death, and one patient died from treatment-related adverse events (myositis in addition to grade 3 thyroiditis,

25 ive cohort, the primary outcomes were treatment failure and adverse events 14 days after diagnosis.

26 urces of referral, body region scanned, type, dose, related adverse events and route of administration of sedatives as we

27 17 (5%) of 370 patients died from non-treatment-related adverse events associated with death, and one patient died fr

28 However, the adverse events associated with smoking limit its clinical sig

29 Adverse events of grade 3 or higher were reported in 87% of t

30 bases were searched for studies in which rates of immediate adverse events to GBCAs were reported.

31 roportion of patients who discontinued treatment because of adverse events was low (range, 0%-1%).

32 Incidence of adverse events was similar in all groups (43 [88%] of 49 in t

33 Treatment-related adverse events were generally grade 1 or 2 in severity.

34 Adverse events were rarely reported.

35 The most frequently observed grade 3 and 4 adverse events were transaminase increases (40% alanine amino

36 eceiving an AI; secondary objectives included evaluation of adverse events, changes in sexual quality of life using the C

37 ent of clinical outcome mainly relies on the declaration of adverse events, identification of their predictors, self-asse

38 ration of abnormal peak flow, antibiotic use, or nonserious adverse events.

39 cceptability of the intervention was high and there were no adverse events.

40 12 patients reported serious adverse events; haemolysis and pyrexia were the most common (

41 dministered calcimimetic could improve adherence and reduce adverse gastrointestinal effects.

42 universally, the efficiency of targeted mutagenesis and the adverse generation of off-target mutations vary greatly betwe

43 ep and circadian disruptions are implicated in a variety of adverse health outcomes, including substance use disorders.

44 enza vaccination during 2013-14 influenza season attenuated adverse outcome among adults that were hospitalized with labo

45 inment of self-harm and violent offending, respectively, as adverse outcomes at ages 15-35 years.

46 Pressure ulcers are serious, avoidable, costly and common adverse outcomes of healthcare.

47 That sex-biased exposure might translate to sex-specific adverse outcomes such as behavioral deficits is a possibility

48 Inpatient hyperglycemia is common and is linked to adverse patient outcomes.

49 Mice with fibroblast-specific Smad3 loss had accentuated adverse remodeling after reperfused infarction and exhibited

50 In adults, high blood pressure (BP), adverse serum lipids, and smoking associate with cognitive de